{"nctId":"NCT00474045","briefTitle":"Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes","startDateStruct":{"date":"2007-05"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"count":470,"armGroups":[{"label":"Insulin detemir","type":"EXPERIMENTAL","interventionNames":["Drug: insulin detemir","Drug: insulin aspart"]},{"label":"Neutral Protamine Hagedorn (NPH) insulin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: NPH insulin","Drug: insulin aspart"]}],"interventions":[{"name":"insulin detemir","otherNames":[]},{"name":"NPH insulin","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 1 diabetes treated with insulin for at least 12 months\n* Planning to become pregnant and have a screening HbA1c (glycosylated haemoglobin) lesser than or equal to 9.0%, or\n* Pregnant with an intrauterine singleton living foetus, 8-12 weeks pregnant when joining the trial and a HbA1c lesser than or equal to 8.0% when pregnancy is confirmed\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to the trial product(s) or related products\n* Untreated hyperthyroidism or hypothyroidism\n* Known or suspected abuse of alcohol or narcotics\n* Cardiac problems\n* Impaired kidney function\n* History of severe hyperemesis gravidarum\n* Treatment with in-vitro fertilisation or other medical infertility treatment\n* Impaired liver function\n* Uncontrolled hypertension\n* Proliferative retinopathy or maculopathy requiring acute treatment\n* Known to be HIV (human immunodeficiency virus) positive, Hepatitis B or Hepatitis C positive\n* Any concomitant medication contraindicated in pregnancy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Glycosylated Haemoglobin (HbA1c) for Full Analysis Set (Pregnant Subjects) at GW 36","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.27","spread":"0.053"},{"groupId":"OG001","value":"6.33","spread":"0.052"}]}]}]},{"type":"PRIMARY","title":"Glycosylated Haemoglobin (HbA1c) for Per Protocol Analysis Set (Pregnant Subjects) at GW 36","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.22","spread":"0.069"},{"groupId":"OG001","value":"6.37","spread":"0.067"}]}]}]},{"type":"SECONDARY","title":"Glycosylated Haemoglobin (HbA1c) During Pregnancy","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.8"},{"groupId":"OG001","value":"6.8","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"0.7"},{"groupId":"OG001","value":"6.5","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"0.7"},{"groupId":"OG001","value":"6.1","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"0.8"},{"groupId":"OG001","value":"6.3","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"0.7"},{"groupId":"OG001","value":"6.5","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"0.9"},{"groupId":"OG001","value":"6.6","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Subjects Reaching HbA1c at or Below 6.0% Both at GW 24 and GW 36","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"2.3"},{"groupId":"OG001","value":"5.8","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"3.0"},{"groupId":"OG001","value":"5.7","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"2.4"},{"groupId":"OG001","value":"6.3","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"1.9"},{"groupId":"OG001","value":"5.4","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"8-point Self-monitored Plasma Glucose (SMPG) Profile at GW 24","description":"8-point SMPG was recorded 3 times prior to each visit, and the average value for each of the 8-time points was applied when presenting and analysing the SMPG data. Visit reallocation was made for the early termination visit and for the withdrawal visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"1.9"},{"groupId":"OG001","value":"7.3","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"2.3"},{"groupId":"OG001","value":"8.0","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"1.9"},{"groupId":"OG001","value":"6.7","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"1.9"},{"groupId":"OG001","value":"7.4","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"2.0"},{"groupId":"OG001","value":"7.0","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"2.0"},{"groupId":"OG001","value":"7.8","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"2.4"},{"groupId":"OG001","value":"7.8","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"2.1"},{"groupId":"OG001","value":"6.9","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"8-point Self Monitored Plasma Glucose (SMPG) Profile at GW 36","description":"8-point SMPG was recorded 3 times prior to each visit, and the average value for each of the 8-time points was applied when presenting and analysing the SMPG data. Visit reallocation was made for the early termination visit and for the withdrawal visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"1.7"},{"groupId":"OG001","value":"6.3","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"2"},{"groupId":"OG001","value":"7.5","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"1.7"},{"groupId":"OG001","value":"6.1","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"1.7"},{"groupId":"OG001","value":"7.1","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"1.7"},{"groupId":"OG001","value":"6.5","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"2.1"},{"groupId":"OG001","value":"7.4","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"1.8"},{"groupId":"OG001","value":"7.2","spread":"2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"1.8"},{"groupId":"OG001","value":"6.4","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Number of Subjects With Adverse Events (AEs)","description":"AE=any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product. Related AE=relationship of probable or possible. Serious adverse event (SAE) =any undesirable serious medical event as defined in protocol.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety in Children - Number of Subjects (Foetuses and Newborns) With Adverse Events","description":"AE=any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product. Related AE=relationship of probable or possible. SAE=any undesirable serious medical event as defined in protocol.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Hypoglycaemic Episodes","description":"All episodes include major, minor and symptoms only. Major episode : unable to self-treat. Minor: able to self-treat and plasma glucose (PG) \\< 3.1 mmol/L. Symptoms only: able to self-treat and no PG measurement or PG glucose ≥3.1 mmol/L. Diurnal: Episode occurring between 06.00 - 00.00, both including.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9496","spread":null},{"groupId":"OG001","value":"9453","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8045","spread":null},{"groupId":"OG001","value":"7810","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Nocturnal Hypoglycaemic Episodes","description":"A nocturnal episode is any episode occurring between 0.01 - 5.59, both including. It includes major, minor and symptoms only episodes. Major: unable to self-treat. Minor: able to self-treat and plasma glucose (PG) \\< 3.1 mmol/L. Symptoms only: able to self-treat and no PG measurement or PG glucose ≥3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1451","spread":null},{"groupId":"OG001","value":"1643","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Albumin Serum Level (Biochemistry)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in albumin level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.05","spread":"0.22"},{"groupId":"OG001","value":"4.04","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.19","spread":"0.25"},{"groupId":"OG001","value":"4.12","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.26"},{"groupId":"OG001","value":"0.09","spread":"0.26"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Alanine Aminotransferase Serum Level (Biochemistry)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in alanine aminotransferase level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.12","spread":"11.31"},{"groupId":"OG001","value":"17.97","spread":"9.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.06","spread":"14.92"},{"groupId":"OG001","value":"26.16","spread":"14.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.88","spread":"17.51"},{"groupId":"OG001","value":"8.16","spread":"15.6"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Alkaline Phosphatase Serum Level (Biochemistry)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in alkaline phosphatase level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.64","spread":"13.63"},{"groupId":"OG001","value":"53.88","spread":"13.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.17","spread":"26.68"},{"groupId":"OG001","value":"92.96","spread":"28.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.39","spread":"20.86"},{"groupId":"OG001","value":"39.51","spread":"23.34"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Creatinine Serum Level (Biochemistry)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in creatinine serum level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.04","spread":"7.85"},{"groupId":"OG001","value":"54.01","spread":"8.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.98","spread":"9.73"},{"groupId":"OG001","value":"66.57","spread":"11.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.18","spread":"7.61"},{"groupId":"OG001","value":"12.52","spread":"8.67"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Lactate Dehydrogenase Serum Level (Biochemistry)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in lactate dehydrogenase serum level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145.1","spread":"34.11"},{"groupId":"OG001","value":"144.1","spread":"24.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167.5","spread":"29.29"},{"groupId":"OG001","value":"169.5","spread":"33.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.82","spread":"33.61"},{"groupId":"OG001","value":"25.46","spread":"30.48"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Potassium Serum Level (Biochemistry)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in potassium serum level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.13","spread":"0.32"},{"groupId":"OG001","value":"4.12","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.30","spread":"0.33"},{"groupId":"OG001","value":"4.31","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.36"},{"groupId":"OG001","value":"0.20","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Sodium Serum Level (Biochemistry)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in sodium serum level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138.0","spread":"2.19"},{"groupId":"OG001","value":"137.8","spread":"2.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141.6","spread":"2.57"},{"groupId":"OG001","value":"141.2","spread":"2.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.59","spread":"3.19"},{"groupId":"OG001","value":"3.36","spread":"3.27"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Total Protein Serum Level (Biochemistry)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in total protein serum level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.84","spread":"0.37"},{"groupId":"OG001","value":"6.89","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.08","spread":"0.44"},{"groupId":"OG001","value":"7.11","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.42"},{"groupId":"OG001","value":"0.22","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Haemoglobin Level (Haematology)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in haemoglobin level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.64","spread":"0.48"},{"groupId":"OG001","value":"7.64","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.81","spread":"0.57"},{"groupId":"OG001","value":"7.69","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.57"},{"groupId":"OG001","value":"0.05","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Leukocytes Level (Haematology)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in leukocytes level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.01","spread":"2.21"},{"groupId":"OG001","value":"8.2","spread":"2.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.68","spread":"1.79"},{"groupId":"OG001","value":"6.55","spread":"1.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"1.93"},{"groupId":"OG001","value":"-1.65","spread":"2.12"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Thrombocytes Level (Haematology)","description":"This is the standard safety lab parameter and is calculated as an estimate of the mean change from Visit P1 in thrombocytes level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"245.3","spread":"48.27"},{"groupId":"OG001","value":"247.2","spread":"59.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"270.6","spread":"66.01"},{"groupId":"OG001","value":"263.1","spread":"68.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.25","spread":"55.07"},{"groupId":"OG001","value":"16.16","spread":"52.02"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Urine Albumin Level (Urinalysis)","description":"This is the standard safety lab parameter and calculated as an estimate of the mean change from Visit P1 in urine albumin level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.02"},{"groupId":"OG001","value":"0.01","spread":"0.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.04"},{"groupId":"OG001","value":"0.03","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.04"},{"groupId":"OG001","value":"0.02","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Albumin/Creatinine Ratio (Urinalysis)","description":"This is the standard safety lab parameter and calculated as an estimate of the mean change from Visit P1 in albumin/creatinine ratio at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"1.4"},{"groupId":"OG001","value":"0.85","spread":"1.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"5.6"},{"groupId":"OG001","value":"4.81","spread":"32.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"5.29"},{"groupId":"OG001","value":"4.07","spread":"32.43"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Urine N (Creatinine) (Urinalysis)","description":"This is the standard safety lab parameter and calculated as an estimate of the mean change from Visit P1 in Urine-N (creatinine) level at Follow-Up Visit (6 weeks after delivery).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114.8","spread":"63.77"},{"groupId":"OG001","value":"103.1","spread":"56.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.2","spread":"66.44"},{"groupId":"OG001","value":"98.61","spread":"58.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.62","spread":"83.83"},{"groupId":"OG001","value":"-6.34","spread":"70.79"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Insulin Detemir Specific Antibodies","description":"Change in concentrations of values for insulin detemir specific antibodies from baseline to Visit P4 was calculated. The unit for measuring antibody levels is amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture (%B/T). Samples were taken before 1st dosing.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":null},{"groupId":"OG001","value":"1.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":null},{"groupId":"OG001","value":"1.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Insulin Aspart Specific Antibodies","description":"Change in concentrations values for insulin aspart specific antibodies from baseline to Visit P4 was calculated. The unit for measuring antibody levels is amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture (%B/T). Samples were taken before 1st dosing.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":null},{"groupId":"OG001","value":"0.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":null},{"groupId":"OG001","value":"0.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":null},{"groupId":"OG001","value":"-0.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change in Insulin Detemir/Insulin Aspart Cross Reacting Antibodies","description":"Change in concentrations values for insulin detemir/aspart cross-reacting antibodies from baseline to Visit P4 was calculated. The unit for measuring antibody levels is amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture (%B/T). Samples were taken before 1st dosing","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.21","spread":null},{"groupId":"OG001","value":"5.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.40","spread":null},{"groupId":"OG001","value":"4.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":null},{"groupId":"OG001","value":"-1.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Pregnancy Outcome Safety - Level of Detemir Specific Antibodies (AB) in Umbilical Cord Blood","description":"Antibodies were measured in a subtraction radioimmunoassay and expressed as antibody bound tracer relative to the total amount of tracer (%B/T).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":null},{"groupId":"OG001","value":"0.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Pregnancy Outcome Safety - Level of Aspart Specific Antibodies (AB) in Umbilical Cord Blood","description":"Antibodies were measured in a subtraction radioimmunoassay and expressed as antibody bound tracer relative to the total amount of tracer (%B/T)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null},{"groupId":"OG001","value":"0.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Pregnancy Outcome Safety - Level of Cross-Reacting Antibodies (AB) in Umbilical Cord Blood","description":"Antibodies were measured in a subtraction radioimmunoassay and expressed as antibody bound tracer relative to the total amount of tracer (%B/T).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.99","spread":null},{"groupId":"OG001","value":"4.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio Between Detemir Specific Antibodies in Cord Blood and Maternal Antibodies","description":"Cord blood (at delivery) vs. Maternal Blood at Visit P4 (GW 36)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":null},{"groupId":"OG001","value":"0.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Pregnancy Outcome Safety - Level of Insulin Detemir in Umbilical Cord Blood","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change From Visit P1 in Body Weight During Pregnancy by Visit","description":"Change in the body weight was summarised by treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":"11.6"},{"groupId":"OG001","value":"69.2","spread":"12.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.6"},{"groupId":"OG001","value":"1.4","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"2.7"},{"groupId":"OG001","value":"6.0","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"4.2"},{"groupId":"OG001","value":"11.0","spread":"5.2"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change From Visit P1 in Systolic Blood Pressure During Pregnancy and at Follow-Up by Visit","description":"Change in the systolic blood pressure was summarised by treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114.1","spread":"11.4"},{"groupId":"OG001","value":"116.2","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"10.1"},{"groupId":"OG001","value":"-2.8","spread":"9.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"9.6"},{"groupId":"OG001","value":"-1.6","spread":"11.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"11.3"},{"groupId":"OG001","value":"2.3","spread":"11.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"11.6"},{"groupId":"OG001","value":"-0","spread":"12.5"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change From Visit P1 in Diastolic Blood Pressure During Pregnancy and at Follow-Up by Visit","description":"Change in the diastolic blood pressure was summarised by treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":"8.9"},{"groupId":"OG001","value":"70.7","spread":"8.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"8.4"},{"groupId":"OG001","value":"-0.5","spread":"9.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"8.7"},{"groupId":"OG001","value":"-1.2","spread":"9.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"9.9"},{"groupId":"OG001","value":"2.6","spread":"11.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"9.5"},{"groupId":"OG001","value":"1.8","spread":"9.8"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Change From Visit P1 in Pulse During Pregnancy and at Follow-Up","description":"Change in the pulse was summarised by treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":"10"},{"groupId":"OG001","value":"76.8","spread":"9.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"9.3"},{"groupId":"OG001","value":"2.2","spread":"10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"10.6"},{"groupId":"OG001","value":"4.5","spread":"10.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"11.8"},{"groupId":"OG001","value":"4.9","spread":"12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"11.7"},{"groupId":"OG001","value":"-2.3","spread":"11.9"}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Electrocardiogram (ECG)","description":"The number of subjects having a electrocardiogram (ECG) that changed from 'Normal' or 'Abnormal, not clinically significant' (at Visit 1, 3 weeks before randomisation) to 'Abnormal, clinically significant' (at Follow-Up). 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Acceleration of Retinopathy in Any Eye","description":"Acceleration of Retinopathy is defined as worsening of fundoscopy/fundusphotography findings from GW 8-12 (Visit P1) to follow-up on one or both eyes.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Acceleration of Nephropathy","description":"Acceleration of nephropathy was defined as a change from a low U-albumin:U-creatinine ratio ≤33.93 mg/mmol to a high U-albumin:U-creatinine ratio \\> 33.93 mg/mmol from GW 8-12 (Visit P1) to the follow-up visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Safety - Mode of Delivery","description":"Non-Planned Caesarean Section is a procedure which takes place ≤8h prior to delivery. Planned Caesarean Section takes place \\>8h prior to delivery.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Pregnancy Outcome at Delivery","description":"Induced abortion means interruption of a living pregnancy \\< 22 completed weeks. Early foetal death means death before 22 completed GWs. Stillbirth indicates death between at or after 22 GW and at or before delivery.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Pregnancy Outcome at Follow-Up","description":"Induced abortion means interruption of a living pregnancy \\< 22 completed weeks. Early foetal death means death before 22 completed GWs. Perinatal Death means death of a foetus/infant between ≥ 22 completed GWs and \\< 1 completed week after delivery. Neonatal Death means death between at or after 7 completed days and before 28 completed days after delivery. Death During Follow-Up means death between at or after 28 days after delivery and at or before Follow-Up.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety - Total Daily Insulin Dose During Pregnancy","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.23"},{"groupId":"OG001","value":"0.74","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"0.29"},{"groupId":"OG001","value":"0.84","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"0.47"},{"groupId":"OG001","value":"1.05","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.17"},{"groupId":"OG001","value":"0.57","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Safety - Composite Pregnancy Outcome","description":"Wt. corresponds to weight of live-born infants. Pre-term delivery: delivery before 37 completed GWs including abortions. Early foetal death: death before 22 completed GWs. Perinatal mortality: death of a foetus/infant between ≥ 22 completed GWs and \\< 1 completed week after delivery. Neonatal mortality: post-partum after 7 completed days and before 28 completed days after delivery. Major-malformation: a life threatening structural anomaly or one likely to cause significant impairment of health or functional capacity and needs medical or surgical treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio Between Aspart Specific Antibodies in Cord Blood and Maternal Antibodies","description":"Cord blood (at delivery) vs. Maternal Blood at Visit P4 (GW 36)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":null},{"groupId":"OG001","value":"0.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio Between Cross-reacting Antibodies in Cord Blood and Maternal Antibodies","description":"Cord blood (at delivery) vs. Maternal Blood at Visit P4 (GW 36)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":null},{"groupId":"OG001","value":"0.90","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":61,"n":152},"commonTop":["Nasopharyngitis","Headache","Anaemia","Diarrhoea","Urinary Tract Infection"]}}}